An approach towards individualized lower rate settings for pacemakers

Margaret Infeld, Robert Avram, Kramer Wahlberg, Daniel N Silverman, Nicole Habel, Daniel L Lustgarten, Mark J Pletcher, Jeffrey E Olgin, Gregory M Marcus, Markus Meyer, Margaret Infeld, Robert Avram, Kramer Wahlberg, Daniel N Silverman, Nicole Habel, Daniel L Lustgarten, Mark J Pletcher, Jeffrey E Olgin, Gregory M Marcus, Markus Meyer

No abstract available

Keywords: Heart failure with preserved ejection fraction; Heart rate; Height; Pacemaker; Personalized.

Conflict of interest statement

Disclosures Dr Meyer and the University of Vermont have licensed patents for the use of pacemakers for the prevention and treatment of heart failure with preserved ejection fraction. Dr Marcus and Dr Meyer have received research funding from Medtronic. The other authors report no conflicts.

Figures

Figure 1
Figure 1
The relationship of growth-associated height and resting heart rate. Linear regression of height and resting heart rate obtained from group medians of national survey and growth chart data.
Figure 2
Figure 2
The relationship of height and resting heart rate in healthy adults. The linear regression of height and resting heart rate from real-world heart rate–photoplethysmography data from the Health-eHeart Study.

References

    1. Lillehei C.W., Gott V.L., Hodges P.C., Jr. Transitor pacemaker for treatment of complete atrioventricular dissociation. J Am Med Assoc. 1960;172:2006–2010.
    1. Ostchega Y., Porter K.S., Hughes J. Resting pulse rate reference data for children, adolescents, and adults: United States, 1999-2008. Natl Health Stat Report. 2011:1–16.
    1. Avram R., Tison G.H., Aschbacher K. Real-world heart rate norms in the Health eHeart study. NPJ Digit Med. 2019;2:58.
    1. Gillis A.M., Russo A.M., Ellenbogen K.A. HRS/ACCF expert consensus statement on pacemaker device and mode selection. Heart Rhythm. 2012;9:1344–1365.
    1. Biffi M., Melissano D., Rossi P. The OPTI-MIND study: a prospective, observational study of pacemaker patients according to pacing modality and primary indications. Europace. 2014;16:689–697.
    1. Meyer M., LeWinter M.M. Heart rate and heart failure with preserved ejection fraction: time to slow beta-blocker use? Circ Heart Fail. 2019;12
    1. Wahlberg K., Arnold M.E., Lustgarten D. Effects of a higher heart rate on quality of life and functional capacity in patients with left ventricular diastolic dysfunction. Am J Cardiol. 2019;124:1069–1075.
    1. CDC Growth Charts. National Center for Health Statistics and the National Center for Chronic Disease Prevention and Health Promotion. May 30, 2000. Accessed February 21, 2020.
    1. O’Rourke M. Churchill-Livingstone; Edinburgh: 1982. Arterial Function in Health and Disease; pp. 170–182.
    1. Jegier W., Sekelj P., Auld P.A. The relation between cardiac output and body size. Br Heart J. 1963;25:425–430.
    1. Smulyan H., Marchais S.J., Pannier B., Guerin A.P., Safar M.E., London G.M. Influence of body height on pulsatile arterial hemodynamic data. J Am Coll Cardiol. 1998;31:1103–1109.
    1. Swedberg K., Komajda M., Bohm M. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
    1. Klein F.J., Bell S., Runte K.E. Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept. Am J Physiol Heart Circ Physiol. 2016;311:H1031–H1039.
    1. Shah S.J., Heitner J.F., Sweitzer N.K. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184–192.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren